Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Haematologica, Vol 92, Issue 9, 1273-1274 doi:10.3324/haematol.11329
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Breccia, M.
Right arrow Articles by Coco, F. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Breccia, M.
Right arrow Articles by Coco, F. L.

Acute Myeloid Leukemia

Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia

Massimo Breccia, Giuseppe Cimino, Daniela Diverio, Fabiana Gentilini, Franco Mandelli, Francesco Lo Coco

Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy (MB, GC, DD, FG,FM); Department of Biopathology, University of Tor Vergata, Rome, Italy (FL-C)

Correspondence: Massimo Breccia, MD, Dept. of Human Biotechnology and Hematology, Via Benevento 6, 00161 Rome, Italy. Phone: international +39.06.857951. Fax: international +39.06.44241984. E-mail: breccia{at}bce.uniroma1.it

We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m2) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.

Key words: acute promyelocytic leukemia, gentuzumab ozogamicin, molecular relapse.






HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2007 by the Ferrata Storti Foundation.